Přihlášení

 
CzMA JEP: Current issue
Archive
Subscription
For authors and reviewers

DIACEREIN (ARTRODAR ® ) - A NEW DRUG FROM THE SYSADOA GROUPIN THE TREATMENT OF OSTEOARTHRITIS

Authors: Pavelková A., Pavelka K.

Authors - sphere of activity: Revmatologický ústav, Praha

Article: Čes. Revmatol., , 2000, No. 2, p. 57-61.
Number of articles displayed: 3710x

Specialization: Dermatology & STDs Paediatric rheumatology Rheumatology

Summary




The authors present the pharmacological profile and an account of the clinical effectiveness ofdiacerein. It is a preparation which inhibits above all the production and activity of interleukin-1(IL-1) as well as other cytokines and catabolic enzymes which participate in the degradation ofcartilage in osteoarthritis (OA). The implemented clinical studies provide evidence of its effective-ness on pain and function in patients with hip and knee osteoarthritis. As to the character of itseffect diacerein belongs to so-called SYSADOA, symptomatically slow acting drugs in OA. The onsetof its effect is as compared with NSA retarded, the onset being after 2-4 weeks. Then its effectivenessis identical as that of NSA. While after discontinuation of NSA treatment the patients exacerbatesas a rule, after termination of diacerein treatment the favourable effect persists for another 2-3months. A recently completed study revealed that in addition to the purely symptomatic effect afterlong-term diacerein treatment the progression of OA is perhaps slower. Thus a drug potentiallymodifying the structure is involved. The assembled results will have to be confirmed in furtherinvestigations. Diacerein is a safe preparation, the main undesirable effect is diarrhoea whichhowever occurs only at the onset of treatment and as a rule does not lead to discontinuation oftherapy.

Key words:
osteoarthritis, diacerein, therapy, SYSADOA

 

Rate article

Rate article:     2,9/5, evaluated 33x
 
 

Recidivující (relabující) polychondritis

M. Kučera, J. Racek, K. Trnavský, J. Herlík 4
Česká revmatologie

Sérová hladina kyseliny hyaluronové – prediktivní biomarker rentgenové progrese osteoartrózy kloubů rukou

Filková M., Šenolt L., Braun M., Hulejová H., Pavelková A., Šléglová O., Kupka K., Gatterová J., Pavelka K.
Česká revmatologie

Leflunomid v současném algoritmu léčby revmatoidní artritidy

Pavelka K., Šedová L.
Česká revmatologie

Asociace mezi svalovou hmotou a zlomeninami u pacientů s anamnézou juvenilní idiopatické artritidy

Brábníková Marešová, K., Jarošová, K., Štěpán, J.
Česká revmatologie

Možnosti predikce rentgenové progrese revmatoidní artritidy

Pavelka K., Gatterová J.
Česká revmatologie

Diferenciální exprese microRNA u systémových autoimunitních onemocnění

Škoda M, Novota P, Pleštilová L, Remáková M, Klein M, Vencovský J
Česká revmatologie

Obezita, tuková tkáň a kardiovaskulární riziko u revmatoidní artritidy

Šenolt L, Kuklová M, Hulejová H, Andres Cerezo L.
Česká revmatologie

 

Most read